Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methadone + bemnifosbuvir + ruzasvir
- Development stage
- Unknown
- Lead developer
- Atea Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methadone + BEM/RZR is an investigational drug regimen consisting of methadone co-administered with a fixed-dose combination (FDC) of bemnifosbuvir (BEM) and ruzasvir (RZR). Methadone is a synthetic mu-opioid receptor agonist used for maintenance therapy in individuals with opioid use disorder. Bemnifosbuvir (AT-527) is an oral, guanosine nucleotide analog prodrug that acts as a pan-genotypic inhibitor of the Hepatitis C Virus (HCV) NS5B RNA-dependent RNA polymerase. Ruzasvir (AT-038) is a potent, pan-genotypic inhibitor of the HCV NS5A protein. This triple combination is primarily studied in Phase 1 drug-drug interaction (DDI) trials by Atea Pharmaceuticals to evaluate the safety and pharmacokinetic profile of the BEM/RZR antiviral regimen in patients receiving stable methadone maintenance therapy for opiate withdrawal.
- Other names
- methadone + bemnifosbuvir/ruzasvirmethadone + AT-527/AT-038
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)RdRp (Coronavirus RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)NMDAR (Glutamate receptor ionotropic, NMDA)KCNH2 (Voltage-gated potassium channel subfamily H member 2)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on methadone + bemnifosbuvir + ruzasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methadone + bemnifosbuvir + ruzasvir.